Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Forxiga CKD Japan Post-Marketing Surveillance (PMS)
Forxiga CKD Japan Post-Marketing Surveillance (PMS)

NCT05306210

CompletedN/A

Sponsor: AstraZeneca

Conditions: Chronic Kidney Disease

Countries: Japan

To capture safety when Forxige is administrated to CKD patients in the real world setting

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Patients with CKD except for dialysis and/or renal failure chronic

Exclusion Criteria:

* None
Locations (46)
  • Aichi, Japan
  • Akita, Japan
  • Aomori, Japan
  • Chiba, Japan
  • Ehime, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Fukushima, Japan
  • Gifu, Japan
  • Gunma, Japan
  • Hiroshima, Japan
  • Hokkaido, Japan
  • Hyōgo, Japan
  • Ibaraki, Japan
  • Ishikawa, Japan
  • Kagawa, Japan
  • Kagoshima, Japan
  • Kanagawa, Japan
  • Kochi, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Mie, Japan
  • Miyagi, Japan
  • Miyazaki, Japan
  • Nagano, Japan
  • Nagasaki, Japan
  • Nara, Japan
  • Niigata, Japan
  • Numakunai, Japan
  • Okayama, Japan
  • + 16 more on CT.gov